

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)



(10) International Publication Number
WO 2021/161283 A1

(51) International Patent Classification:

A61K 31/122 (2006.01) C07C 50/14 (2006.01)
A61K 9/127 (2006.01) C07C 50/18 (2006.01)
C07C 50/12 (2006.01) A61P 31/14 (2006.01)

(21) International Application Number:

PCT/IB2021/051256

(22) International Filing Date:

15 February 2021 (15.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/976,420 14 February 2020 (14.02.2020) US

(71) Applicant: NLC PHARMA LTD [IL/IL]; B.S.R Tower
No. 4, 7 Mesada Street, 26th Floor, 5126112 Bnei-Brak (IL).

(72) Inventor: ARAD, Dorit; 1 Bareli Street, Apt 8, 6936452
Tel Aviv (IL).

(74) Agent: G. E. EHRLICH (1995) LTD. et al.; 11 Menachem
Begin Road, 5268104 Ramat-Gan (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS FOR TREATING CORONAVIRUS INFECTION





FIG. 2



(57) Abstract: Described herein are compounds of Formula I: wherein R₁-R₆ are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3 CL protease, by contacting the 3 CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3 CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.